Notice Regarding Resolution for Convening an Extraordinary Shareholders' Meeting of Daewoong Pharmaceutical

Hello everyone! Today, we're bringing you news from Daewoong Pharmaceutical regarding their upcoming extraordinary shareholders' meeting scheduled for September 9th. This meeting will address the agenda item of the separate election of an independent director who will also serve as an auditor, in accordance with the amendment to the Commercial Act. We know many of you are curious about this, so let's dive into the details together.

Extraordinary Shareholders' Meeting Schedule and Venue

Daewoong Pharmaceutical's extraordinary shareholders' meeting will be held on September 9, 2026, at 9:00 AM at the Bear Hall, located at 12, Bongeunsa-ro 114-gil, Gangnam-gu, Seoul (B1). The record date for exercising voting rights for this meeting is August 12, 2026, and the board resolution was made on July 28, 2026. Four outside directors attended this board meeting to make the decisions.

Meeting Agenda and Reports

At this extraordinary shareholders' meeting, an important report on auditing will be presented. Additionally, the agenda item will include the first proposal: the appointment of Kwon Soon-yong as an independent director to serve as an auditor. Daewoong Pharmaceutical explained that this appointment is a measure to fulfill the required number of auditors to be elected separately, as stipulated by the amendment to the Commercial Act. The term for this independent director will be three years, valid until the conclusion of the general meeting of shareholders concerning the final fiscal year.

Director Kwon Soon-yong's Career

Director Kwon Soon-yong, who is slated for appointment, was born in March 1960 and is eligible for re-appointment. His notable career includes:

• Ph.D. from the Graduate School of Medicine, The Catholic University of Korea
• Clinical Chief of Orthopedics, St. Mary's Hospital, Yeouido
• Professor and Head of the Department of Orthopedics, The Catholic University of Korea
• Medical Director, St. Mary's Hospital, Yeouido, The Catholic University of Korea
• 11th Hospital Director, St. Paul's Hospital, The Catholic University of Korea
• Founding Hospital Director, Eunpyeong St. Mary's Hospital, The Catholic University of Korea

He is currently an Emeritus Professor of Orthopedics at Seoul St. Mary's Hospital, The Catholic University of Korea, and also serves as an outside director for i-VEX Medical Systems. His position as an auditor will be as an outside director serving as an auditor, with a three-year term.

Daewoong Pharmaceutical's Financial Status

Looking at Daewoong Pharmaceutical's consolidated financial status as of the fiscal year ending December 2025, the total assets stand at 2.3628 trillion KRW, total liabilities at 1.2281 trillion KRW, and total equity at 1.1347 trillion KRW. Revenue reached 1.5709 trillion KRW, operating profit was 196.8 billion KRW, and net profit was 192.9 billion KRW. This indicates that Daewoong Pharmaceutical maintains a stable financial structure, and continued growth is anticipated.

Finally, as of 4:10 PM on July 28, 2026, Daewoong Pharmaceutical's stock price was 125,900 KRW, a decrease of 2,400 KRW (-1.87%) from the previous day. These stock prices may fluctuate based on future business performance, so continued attention is advised.

We ask for your continued interest and support for Daewoong Pharmaceutical's future endeavors. Thank you!